Efficacy of anti-SARS-CoV-2 vaccines in specific categories of patients, due to the lack of validated diagnostic procedures, has been even less assessed; nevertheless, a good protection from severe forms of COVID-19 seems to be provided also in patients affected by rheumatic diseases [37] in general and IIM in particular [38], despite a lower rate in seroconversion in subjects treated with anti-CD20 and anti-CTLA-4 agents [39, 40]. Here, CTLA4 is linked to rheumatic disorder.